Equities research analysts expect Moderna Inc (NASDAQ) (NYSE:MRNA) to post sales of $33.59 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Moderna Inc (NASDAQ)’s earnings. The lowest sales estimate is $33.00 million and the highest is $34.00 million. The firm is expected to issue its next quarterly earnings results on Wednesday, June 12th.
On average, analysts expect that Moderna Inc (NASDAQ) will report full year sales of $133.26 million for the current financial year, with estimates ranging from $120.04 million to $143.20 million. For the next year, analysts expect that the company will post sales of $109.47 million, with estimates ranging from $10.55 million to $136.29 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Moderna Inc (NASDAQ).
Separately, Chardan Capital reaffirmed a “buy” rating on shares of Moderna Inc (NASDAQ) in a research note on Sunday, April 7th.
Moderna Inc (NASDAQ) Company Profile
Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
Featured Story: What is the Consumer Price Index (CPI)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Moderna Inc (NASDAQ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna Inc (NASDAQ) and related companies with MarketBeat.com's FREE daily email newsletter.